Inflammatory bowel disease treatments and predictive biomarkers of therapeutic response
Inflammatory bowel disease (IBD) is a chronic immune-mediated inflammation of the
gastrointestinal tract with a highly heterogeneous presentation. It has a relapsing and …
gastrointestinal tract with a highly heterogeneous presentation. It has a relapsing and …
Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and meta-analysis
Background & Aims Safety is a key consideration when choosing advanced therapies
(biologic agents and oral small-molecule inhibitors/modulators) in patients with inflammatory …
(biologic agents and oral small-molecule inhibitors/modulators) in patients with inflammatory …
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre …
Background Active-comparator trials are important to inform patient and physician choice.
We aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or …
We aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or …
[HTML][HTML] A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE) …
Background Management strategies and clinical outcomes vary substantially in patients
newly diagnosed with Crohn's disease. We evaluated the use of a putative prognostic …
newly diagnosed with Crohn's disease. We evaluated the use of a putative prognostic …
Recent advances in understanding Nrf2 agonism and its potential clinical application to metabolic and inflammatory diseases
Oxidative stress is a major component of cell damage and cell fat, and as such, it occupies a
central position in the pathogenesis of metabolic disease. Nuclear factor-erythroid-derived 2 …
central position in the pathogenesis of metabolic disease. Nuclear factor-erythroid-derived 2 …
Early ileocecal resection for crohn's disease is associated with improved long-term outcomes compared with anti-tumor necrosis factor therapy: a population-based …
Background & Aims Early Crohn's disease (CD) treatment involves anti-tumor necrosis factor
(TNF) agents, whereas ileocecal resection (ICR) is reserved for complicated CD or treatment …
(TNF) agents, whereas ileocecal resection (ICR) is reserved for complicated CD or treatment …
Epidemiology and natural history of perianal Crohn's disease: a systematic review and meta-analysis of population-based cohorts
Abstract Background and Aims Perianal Crohn's disease (pCD) is a potentially severe
phenotype of CD. We conducted a systematic review with meta-analysis to estimate …
phenotype of CD. We conducted a systematic review with meta-analysis to estimate …
AGA clinical practice guideline on the management of pouchitis and inflammatory pouch disorders
Background & Aims Pouchitis is the most common complication after restorative
proctocolectomy with ileal pouch–anal anastomosis for ulcerative colitis. This American …
proctocolectomy with ileal pouch–anal anastomosis for ulcerative colitis. This American …
A review of the therapeutic management of Crohn's disease
A Kumar, A Cole, J Segal, P Smith… - Therapeutic Advances …, 2022 - journals.sagepub.com
Crohn's disease is a chronic inflammatory, relapsing-remitting, and progressive
gastrointestinal disorder with an often-negative impact on the physical, emotional, and …
gastrointestinal disorder with an often-negative impact on the physical, emotional, and …
Korean clinical practice guidelines on biologics for moderate to severe Crohn's disease
Crohn's disease (CD) is a relapsing and progressive condition characterized by diarrhea,
abdominal pain, weight loss, and hematochezia that results in serious complications such as …
abdominal pain, weight loss, and hematochezia that results in serious complications such as …